DaVita, Inc. Hits New 52-Week High of $205.33, Reflecting Strong Growth

DaVita, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 205.33 on June 11, 2026. This achievement underscores the stock's impressive performance over the past year, with a notable increase of 43.97%, significantly outpacing the S&P 500's growth of 22.78% during the same period. The company's market capitalization stands at USD 11,513 million, reflecting its position within the small-cap category. DaVita's price-to-earnings (P/E) ratio is currently at 11.00, indicating a valuation that may attract attention in the context of its industry. However, the company does not offer a dividend yield, and its return on equity is reported at -163.56%, alongside a debt-to-equity ratio of -15.25, which may raise questions about its financial leverage. With the stock's 52-week low recorded at USD 101, the recent high marks a significant recovery and performance improvement for DaVita, Inc. as it navigates the competitive landscape of the pharmaceuticals and biotechnology industry.